<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04008511</url>
  </required_header>
  <id_info>
    <org_study_id>CLOG1901</org_study_id>
    <secondary_id>IMPACT 20872</secondary_id>
    <nct_id>NCT04008511</nct_id>
  </id_info>
  <brief_title>Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancer</brief_title>
  <official_title>Phase Ib/II Study of Regorafenib and XELOX Combination as 2nd Line Treatment in Metastatic Colorectal Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Medical University, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Liaoning Tumor Hospital &amp; Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First People's Hospital of Jingzhou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>China Medical University, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an interventional, randomized open-label, parallel-group, multicenter, dose
      escalation phase Ib/II study, to investigate the combination of Regorafenib and XELOX as 2nd
      line treatment in mCRC patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase Ib/II trial, comprising Phase Ib and Phase II two parts. Phase Ib study is an
      open-label, single-arm, multicenter, dose escalation study of Regorafenib plus XELOX. In
      Phase Ib, max 15 patients(pts) could be enrolled based on the modified toxicity probability
      interval (mTPI) design. Phase II study is a randomized, open-label, parallel-group,
      multicenter study comparing Regorafenib + XELOX to XELOX alone. In phase II trial, a total of
      39 patients will be recruited and randomized 2:1 into two groups, where 26 patients under
      Regorafenib + XELOX, and 13 patients under XELOX alone.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2019</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>6 weeks</time_frame>
    <description>The MTD is defined as the highest dose that can be given so that toxicity probability is below the target toxicity PT=30%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>1 year</time_frame>
    <description>PFS is defined as the time (days) from start of study treatment to date of first observed disease progression (investigator's radiological or clinical assessment) or death due to any cause, if death occurs before progression is documented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0</measure>
    <time_frame>3 years</time_frame>
    <description>Safety and tolerability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>3 years</time_frame>
    <description>o DCR is defined as the percentage of patients, whose overall best response was not progressive disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>3 years</time_frame>
    <description>o ORR is defined as the percentage of patients with complete response (CR) or partial response (PR).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Phase Ib: Regorafenib plus XELOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase Ib followed a Modified toxicity probability interval (mTPI) design to determine the maximum administered dose (MAD), there are 3 dose levels, and the dose level started from Group A:
Group A: Regorafenib 120mg + XELOX; Group B: Regorafenib 160mg + XELOX; Group C: Regorafenib 80mg + XELOX. (Regorafenib qd po for 14 days, every 3 weeks; XELOX: Oxaliplatin 130 mg/m2 IV, day 1, Capecitabine 1000 mg/m2 bid po for 14 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II: Regorafenib plus XELOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regorafenib MAD qd po for 14 days, every 3 weeks, Oxaliplatin 130 mg/m2 IV on day 1, Capecitabine 1000 mg/m2 bid po for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II: XELOX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxaliplatin 130 mg/m2 IV on day 1, Capecitabine 1000 mg/m2 bid po for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regorafenib</intervention_name>
    <description>Phase Ib Group A: Regorafenib 120mg + XELOX; Group B: Regorafenib 160mg + XELOX; Group C: Regorafenib 80mg + XELOX.</description>
    <arm_group_label>Phase Ib: Regorafenib plus XELOX</arm_group_label>
    <other_name>Stivarga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regorafenib</intervention_name>
    <description>Phase II: Regorafenib MAD qd po for 14 days, every 3 weeks.</description>
    <arm_group_label>Phase II: Regorafenib plus XELOX</arm_group_label>
    <other_name>Stivarga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine 1000 mg/m2 bid po for 14 days.</description>
    <arm_group_label>Phase II: Regorafenib plus XELOX</arm_group_label>
    <arm_group_label>Phase II: XELOX</arm_group_label>
    <arm_group_label>Phase Ib: Regorafenib plus XELOX</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Oxaliplatin 130mg/m2, day 1, every 3 weeks</description>
    <arm_group_label>Phase II: Regorafenib plus XELOX</arm_group_label>
    <arm_group_label>Phase II: XELOX</arm_group_label>
    <arm_group_label>Phase Ib: Regorafenib plus XELOX</arm_group_label>
    <other_name>ELOXATIN®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Sign a consent form

          2. Age&gt; 18 years &lt;75 years

          3. Pathological diagnosis as colorectal adenocarcinoma

          4. Recurrence or metastatic disease

          5. Metastatic colorectal cancer with disease progression after 1st line treatment by 5-Fu
             and Irinotecan

          6. Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST)

          7. ECOG score 0-1 points

          8. Life expectancy ≥3 months

          9. Can provide more than 10 paraffin sections of tumor tissue

         10. End of radiotherapy without or with non-targeted lesions&gt; 4 weeks (only for use
             outside of the test site)

         11. At least one measurable lesion (according to RECIST 1.1)

         12. Previously treated radiotherapy lesions cannot be considered as target lesions, unless
             the radiotherapy lesions clear progress.

         13. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)≤ 2.5 times the
             upper limit of normal (ULN), patients with liver metastases ≤ 5 times ULN

         14. Serum albumin ≥ 3.0g / dL

         15. Serum alkaline phosphatase (AKP) ≤2.5 times ULN

         16. Total bilirubin &lt;1.5mg / dL

         17. Estimated creatinine clearance (CLcr) ≥ 30 mL/min as calculated using the
             Cockcroft-Gault equation

         18. Lipase ≤ 1.5 x the ULN

         19. Neutrophil absolute count (ANC) ≥ 1500 / mm3, hemoglobin (Hb)&gt; 9g/dl, platelets&gt;
             100,000 / mm3

         20. Pregnant or breast-feeding patients:

        1) Women of childbearing potential and men must agree to use adequate contraception before
        entering the program until at least 8 weeks after the last study drug administration. The
        investigator or a designated associate is requested to advise the subject on how to achieve
        an adequate birth control. Adequate contraception is defined in the study as any medically
        recommended method (or combination of methods) as per standard of care.

        2) Women of childbearing potential must have a blood or urine pregnancy test performed a
        maximum of 7 days before start of study treatment, and a negative result must be documented
        before start of study treatment

        Exclusion Criteria:

          1. Received oxaliplatin and capecitabine in the 1st line treatment

          2. Cannot be orally administered

          3. Subjects with brain metastases and / or cancerous meningitis.

          4. Surgical treatment was performed within 4 weeks before enrollment (excluding
             diagnostic biopsies)

          5. Non-healing wound, non-healing ulcer, or non-healing bone fracture

          6. Patients with evidence or history of any bleeding diathesis, irrespective of severity

          7. Any hemorrhage or bleeding event ≥ CTCAE Grade 3 within 4 weeks prior to the start of
             study medication.

          8. Arterial or venous thrombotic or embolic events such as cerebrovascular accident
             (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism
             within 6 months before the start of study medication (except for adequately treated
             catheter-related venous thrombosis occurring more than one month before the start of
             study medication)

          9. Congestive heart failure ≥ New York Heart Association (NYHA) class 2

         10. Uncontrolled cardiac arrhythmias

         11. Ongoing infection &gt; Grade 2 NCI CTCAE

         12. Interstitial lung disease with ongoing signs and symptoms at the time of informed
             consent.

         13. Known hypersensitivity to any of the study drugs, study drug classes, or excipients in
             the formulation.

         14. Anti-tumor cytotoxic drug therapy, biologic medication (eg, monoclonal antibody),
             immunotherapy (eg, interleukin 2 or interferon), or other investigational drug therapy
             within 4 weeks prior to enrollment

         15. Subjects with active tuberculosis (TB) who are on anti-TB treatment or who have
             received anti-TB treatment within 1 year prior to screening

         16. Patients with complications requiring long-term use of immunosuppressive drug therapy
             or systemic or topical corticosteroids requiring immunosuppressive doses (prednisone
             or other equivalent hormones at doses&gt; 10 mg / day)

         17. Use of strong CYP3A4 inducers or inhibitors

         18. In the first 4 weeks before the group vaccinated any anti-infective vaccine (such as
             influenza vaccine, varicella vaccine, etc.)

         19. Pregnancy or lactation

         20. 5 years with other malignancies, except for non-melanoma skin cancer

         21. Persistent proteinuria &gt; 3.5 g/24 hours measured by urine protein-creatinine ratio
             from a random urine sample (Grade 3, NCI-CTCAE v 5.0).

         22. Human immunodeficiency virus (HIV) positive

         23. Hepatitis B surface antigen (HBsAg) positive simultaneous detection of Hepatitis B
             virus (HBV) Deoxyribonucleic acid (DNA) copy number positive (quantitative detection ≥
             1000cps / ml)

         24. Chronic hepatitis C blood screening positive [Hepatitis C virus (HCV) antibody
             positive]

         25. No legal capacity

         26. Any other disease or condition that the investigator considers may affect program
             adherence or affect the subject's signature of informed consent (ICF), or are not
             suitable for participating in this clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yunpeng Liu, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Hospital of China Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yunpeng Liu, M.D.,Ph.D.</last_name>
    <phone>86-24-83282312</phone>
    <email>cmu_trial@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiujuan Qu, M.D.,Ph.D.</last_name>
    <phone>86-24-83282312</phone>
    <email>cmuquxiujuan@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 2, 2019</study_first_submitted>
  <study_first_submitted_qc>July 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2019</study_first_posted>
  <last_update_submitted>July 3, 2019</last_update_submitted>
  <last_update_submitted_qc>July 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>China Medical University, China</investigator_affiliation>
    <investigator_full_name>Yunpeng Liu</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>Metastatic Colorectal Cancer</keyword>
  <keyword>Regorafenib</keyword>
  <keyword>Second line</keyword>
  <keyword>XELOX</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

